Dramatic early improvement of psoriasis in an 11‐year old boy after four doses of secukinumab following an alternative dosing scheme
Author:
Affiliation:
1. Department of Dermatology Hochgebirgsklinik Davos Switzerland
2. Christine Kühne Center for Allergy Research and Education Davos Switzerland
3. Department of Dermatology University of Zurich Zurich Switzerland
Publisher
Wiley
Subject
Infectious Diseases,Dermatology
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1111/jdv.19620
Reference5 articles.
1. The epidemiology of childhood psoriasis: a scoping review;Burden‐The E;Br J Dermatol,2016
2. Swiss Agency for Therapeutic Products.www.swissmedicinfo.ch. Accessed October 12 2023.
3. A phase 3 open label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24‐week results;Magnolo N;J Am Acad Dermatol,2022
4. Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52‐week results from a phase 3 double‐blind randomized, controlled trial;Bodemer C;J Eur Acad Dermatol Venereol,2021
5. Secukinumab for recalcitrant chronic plaque psoriasis in a 9 year old child;Shruthi R;Indian J Dermatol,2021
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3